• 1.

    Walker SL et al.2017. A leprosy clinical severity scale for erythema nodosum leprosum: an international, multicentre validation study of the ENLIST ENL Severity Scale. PLoS Negl Trop Dis 11: e0005716.

    • Search Google Scholar
    • Export Citation
  • 2.

    Voorend CG, Post EB, 2013. A systematic review on the epidemiological data of erythema nodosum leprosum, a type 2 leprosy reaction. PLoS Negl Trop Dis 7: e2440.

    • Search Google Scholar
    • Export Citation
  • 3.

    Narang T, Kamat D, 2020. Reactions in leprosy. Sardana K, Khurana A, eds. Jopling’s Handbook of Leprosy, 6th edition. New Delhi, India: CBS, 212–213.

  • 4.

    Sardana K et al.2020. Late leprosy reaction presenting as erythema multiforme-like erythema nodosum leprosum with underlying rifampicin resistance and its potential implications. Int J Mycobacteriol 9: 226228.

    • Search Google Scholar
    • Export Citation
  • 5.

    Upputuri B, Pallapati MS, Tarwater P, Srikantam A, 2020. Thalidomide in the treatment of erythema nodosum leprosum (ENL) in an outpatient setting: a five-year retrospective analysis from a leprosy referral centre in India. PLoS Negl Trop Dis 14: e0008678.

    • Search Google Scholar
    • Export Citation
  • 6.

    Teo S et al.2002. Thalidomide in the treatment of leprosy. Microbes Infect 4: 11931202.

  • 7.

    Villahermosa LG et al.2005. A randomized, double-blind, double-dummy, controlled dose comparison of thalidomide for treatment of erythema nodosum leprosum. Am J Trop Med Hyg 72: 518526.

    • Search Google Scholar
    • Export Citation
  • 8.

    Nabarro LE et al.2016. The use of steroids and thalidomide in the management of erythema nodosum leprosum: 17 years at the Hospital for Tropical Diseases, London. Lepr Rev 87: 221231.

    • Search Google Scholar
    • Export Citation
  • 9.

    Walker SL, Waters MF, Lockwood DN, 2007. The role of thalidomide in the management of erythema nodosum leprosum. Lepr Rev 78: 197215.

  • 10.

    Khurana A, Sardana K, Sardana K & Khurana A Jopling’s Handbook of Leprosy, 6th edition. New Delhi, India: CBS, 182191.

  • 11.

    Haslett PA et al.2005. Effective treatment of erythema nodosum leprosum with thalidomide is associated with immune stimulation. J Infect Dis 192: 20452053.

    • Search Google Scholar
    • Export Citation
  • 12.

    Shannon E, Noveck R, Sandoval F, Kamath B, 2008. Thalidomide suppressed IL-1beta while enhancing TNF-alpha and IL-10, when cells in whole blood were stimulated with lipopolysaccharide. Immunopharmacol Immunotoxicol 30: 447457.

    • Search Google Scholar
    • Export Citation
  • 13.

    Pacheco FS et al.2020. Erythema nodosum leprosum neutrophil subset expressing IL-10R1 transmigrates into skin lesions and responds to IL-10. Immunohorizons 4: 4756.

    • Search Google Scholar
    • Export Citation
  • 14.

    da Silva CO et al.2019. Neutrophil extracellular traps contribute to the pathogenesis of leprosy type 2 reactions. PLoS Negl Trop Dis 13: e0007368.

    • Search Google Scholar
    • Export Citation
  • 15.

    Yasui K, Kobayashi N, Yamazaki T, Agematsu K, 2005. Thalidomide as an immunotherapeutic agent: the effects on neutrophil-mediated inflammation. Curr Pharm Des 11: 395401.

    • Search Google Scholar
    • Export Citation
  • 16.

    Sampaio EP et al.1993. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 168: 408414.

    • Search Google Scholar
    • Export Citation
  • 17.

    Oliveira RB, Moraes MO, Oliveira EB, Sarno EN, Nery JA, Sampaio EP, 1999. Neutrophils isolated from leprosy patients release TNF-alpha and exhibit accelerated apoptosis in vitro. J Leukoc Biol 65: 364371.

    • Search Google Scholar
    • Export Citation
Past two years Past Year Past 30 Days
Abstract Views 7116 7116 42
Full Text Views 40 40 7
PDF Downloads 44 44 7
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 

 

 

Case Report: Rapid Response to Low-Dose Thalidomide in a Case of Severe Steroid Recalcitrant Erythema Nodosum Leprosum

Bathula SavithaDepartment of Dermatology, Venereology and Leprosy, ABVIMS and Dr. Ram Manohar Lohia Hospital, New Delhi, India

Search for other papers by Bathula Savitha in
Current site
Google Scholar
PubMed
Close
,
Kabir SardanaDepartment of Dermatology, Venereology and Leprosy, ABVIMS and Dr. Ram Manohar Lohia Hospital, New Delhi, India

Search for other papers by Kabir Sardana in
Current site
Google Scholar
PubMed
Close
,
Ritu KumariDepartment of Dermatology, Venereology and Leprosy, ABVIMS and Dr. Ram Manohar Lohia Hospital, New Delhi, India

Search for other papers by Ritu Kumari in
Current site
Google Scholar
PubMed
Close
,
Ananta KhuranaDepartment of Dermatology, Venereology and Leprosy, ABVIMS and Dr. Ram Manohar Lohia Hospital, New Delhi, India

Search for other papers by Ananta Khurana in
Current site
Google Scholar
PubMed
Close
,
Surabhi SinhaDepartment of Dermatology, Venereology and Leprosy, ABVIMS and Dr. Ram Manohar Lohia Hospital, New Delhi, India

Search for other papers by Surabhi Sinha in
Current site
Google Scholar
PubMed
Close
, and
Soumya SachdevaDepartment of Dermatology, Venereology and Leprosy, ABVIMS and Dr. Ram Manohar Lohia Hospital, New Delhi, India

Search for other papers by Soumya Sachdeva in
Current site
Google Scholar
PubMed
Close
Restricted access

ABSTRACT.

Erythema nodosum leprosum (ENL), or type 2 lepra reaction, presents with crops of evanescent, tender erythematous nodules accompanied by fever, arthralgia, malaise and organ-specific manifestations and is seen in borderline and lepromatous leprosy. The drugs approved for ENL include nonsteroidal anti-inflammatory drugs, systemic steroids, thalidomide and clofazimine. The management of ENL is challenging because long-term steroid use leads to steroid dependence. The present patient had severe steroid recalcitrant ENL with vesicular and pustular lesions mimicking Sweet’s syndrome and was treated effectively with a low-dose thalidomide regimen (100 mg/d) as opposed to high dose (400 mg/d) recommended in literature. We discuss the patho-mechanics and clinical utility of a low-dose thalidomide regimen as an effective treatment option for ENL.

Author Notes

Address correspondence to Kabir Sardana, Department of Dermatology, Venereology and Leprosy, ABVIMS & Dr. Ram Manohar Lohia Hospital, New Delhi, India. E-mail: kabirijdvl@gmail.com

Authors’ addresses: Bathula Savitha, Kabir Sardana, Ritu Kumari, Ananta Khurana, Surabhi Sinha, and Soumya Sachdeva, Department of Dermatology, Venereology and Leprosy, ABVIMS and Dr. Ram Manohar Lohia Hospital, New Delhi, India, E-mails: savitharavivarma@gmail.com, kabirijdvl@gmail.com, ritu64026@gmail.com, drananta2014@gmail.com, surabhi2310@gmail.com, and soumyasachdeva1402@gmail.com.

Save